10,846 Shares in AbbVie Inc. $ABBV Bought by 49 Wealth Management LLC

Key Points

• 49 Wealth Management LLC acquired 10,846 AbbVie shares worth approximately $2.73 million, making ABBV its 27th-largest holding and about 0.3% of its portfolio. Institutional investors and hedge funds collectively own 70.23% of the stock.
• Analysts maintain a favorable outlook, with AbbVie receiving a consensus “Moderate Buy” rating and an average price target of $275.95. The company recently exceeded quarterly earnings and revenue expectations, reporting $3.65 EPS and $16.99 billion in revenue.
• AbbVie declared a quarterly dividend of $1.73 per share, equivalent to a 2.7% annualized yield, while investors weigh growth from newer drugs and pipeline assets against declining Humira revenue and an insider’s sale of 32,710 shares.

49 Wealth Management LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 10,846 shares of the company's stock, valued at approximately $2,729,000. AbbVie makes up about 0.3% of 49 Wealth Management LLC's portfolio, making the stock its 27th biggest holding.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ABBV. Burk Holdings LLC acquired a new stake in AbbVie in the 2nd quarter valued at $30,000. Litman Gregory Wealth Management LLC bought a new stake in AbbVie during the 4th quarter worth about $28,000. Imprint Wealth LLC boosted its stake in shares of AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock worth $29,000 after buying an additional 45 shares during the last quarter. IFC & Insurance Marketing Inc. acquired a new position in shares of AbbVie during the 4th quarter worth about $31,000. Finally, Legacy Wealth Managment LLC ID grew its holdings in shares of AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock valued at $31,000 after acquiring an additional 73 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ABBV shares. Weiss Ratings upgraded AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a report on Tuesday, August 4th. Piper Sandler raised their price target on AbbVie from $298.00 to $303.00 and gave the company an "overweight" rating in a research note on Thursday, August 20th. Morgan Stanley reaffirmed an "overweight" rating and set a $296.00 price target on shares of AbbVie in a research report on Monday, August 3rd. Evercore set a $235.00 price objective on AbbVie in a research note on Friday, May 15th. Finally, Citigroup increased their price objective on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a report on Wednesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $275.95.

AbbVie Stock Down 0.1%

Shares of NYSE ABBV opened at $256.27 on Monday. The business's 50 day moving average price is $254.66 and its two-hundred day moving average price is $230.05. The company has a market cap of $452.78 billion, a PE ratio of 72.39, a price-to-earnings-growth ratio of 1.16 and a beta of 0.29. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. During the same period last year, the firm posted $2.97 earnings per share. The business's revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a dividend of $1.73 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie's dividend payout ratio (DPR) is currently 195.48%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial
• Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics
• Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case.
• Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics
• Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.06% of the stock is currently owned by company insiders.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.